- Kodiak Sciences Inc's KOD BEACON Phase 3 study of tarcocimab tedromer met the primary endpoint of non-inferior change from baseline in visual acuity in macular edema due to retinal vein occlusion (RVO).
- Tarcocimab also demonstrated robust anatomic responses and a favorable safety profile.
- After two initial monthly loading doses, tarcocimab was dosed every two months compared to consistent monthly dosing for Regeneron Pharmaceuticals Inc's REGN Eylea (aflibercept).
- The non-inferiority margin for the comparison to aflibercept at week 24 was established at 4.5 eye chart letters.
- Tarcocimab tedromer was safe and well tolerated in the study, with no new safety signals identified. A low rate of intraocular inflammation was observed in both groups (1.4% vs. 0.4% for tarcocimab and aflibercept, respectively), with no vasculitis or retinal arterial occlusion events reported in any patient.
- Full primary results from the BEACON study are expected to be presented by BEACON Study Investigators at upcoming ophthalmology congresses in September 2022.
- Price Action: KOD shares are up 30.38% at $12.60 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
